奥拉帕利用于前列腺切除术后高危生化复发前列腺癌 - Suppr

[Olaparib for high-risk biochemically recurrent prostate cancer following prostatectomy].

作者信息

Hintelmann Katharina, Böckelmann Lukas

机构信息

Klinik für Strahlentherapie und Ambulanzzentrum der UKE GmbH, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland.

出版信息

Strahlenther Onkol. 2025 Mar;201(3):343-345. doi: 10.1007/s00066-024-02350-3. Epub 2024 Dec 17.

DOI:10.1007/s00066-024-02350-3

PMID:39690262

Abstract

摘要

相似文献

[Olaparib for high-risk biochemically recurrent prostate cancer following prostatectomy].奥拉帕利用于前列腺切除术后高危生化复发前列腺癌

Strahlenther Onkol. 2025 Mar;201(3):343-345. doi: 10.1007/s00066-024-02350-3. Epub 2024 Dec 17.

Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial.奥拉帕利治疗前列腺癌术后生化复发高危患者的疗效：一项非随机对照试验

JAMA Oncol. 2024 Oct 1;10(10):1400-1408. doi: 10.1001/jamaoncol.2024.3074.

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).根治性前列腺切除术后高危 PSA 复发前列腺癌的挽救性放疗加安慰剂与 SRT 加恩扎鲁胺的 II 期随机安慰剂对照双盲研究（SALV-ENZA）。

BMC Cancer. 2019 Jun 13;19(1):572. doi: 10.1186/s12885-019-5805-z.

Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.醋酸阿比特龙联合泼尼松治疗非转移性生化复发的去势敏感前列腺癌。

Eur J Cancer. 2021 Nov;157:259-267. doi: 10.1016/j.ejca.2021.06.017. Epub 2021 Sep 15.

Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy.99mTc-HYNIC-PSMA SPECT/CT对前列腺癌根治术后生化复发前列腺癌的诊断性能

Front Oncol. 2022 Dec 7;12:1072437. doi: 10.3389/fonc.2022.1072437. eCollection 2022.

Management Options for Biochemically Recurrent Prostate Cancer.生化复发前列腺癌的管理选择

Curr Treat Options Oncol. 2017 May;18(5):26. doi: 10.1007/s11864-017-0462-4.

A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌的新用途。

Pharmacotherapy. 2017 Nov;37(11):1406-1414. doi: 10.1002/phar.2027.

Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer.奥拉帕利和度伐利尤单抗用于DNA损伤修复改变和生化复发前列腺癌患者的研究

J Immunother Precis Oncol. 2025 Apr 23;8(2):172-176. doi: 10.36401/JIPO-24-36. eCollection 2025 May.

PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.PSA 倍增时间和绝对 PSA 可预测前列腺癌根治术后生化复发的男性无转移生存。

Clin Genitourin Cancer. 2019 Dec;17(6):470-475.e1. doi: 10.1016/j.clgc.2019.08.002. Epub 2019 Aug 21.

Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.根治性前列腺切除术后高风险前列腺特异性抗原复发前列腺癌的挽救性放疗加恩扎鲁胺或安慰剂的 II 期随机研究：SALV-ENZA 试验。

J Clin Oncol. 2023 Feb 20;41(6):1307-1317. doi: 10.1200/JCO.22.01662. Epub 2022 Nov 11.

本文引用的文献

JAMA Oncol. 2024 Oct 1;10(10):1400-1408. doi: 10.1001/jamaoncol.2024.3074.

Parp Inhibitors and Radiotherapy: A New Combination for Prostate Cancer (Systematic Review).聚腺苷二磷酸核糖聚合酶抑制剂与放射治疗联合用于前列腺癌的新方案（系统评价）。

Int J Mol Sci. 2023 Aug 19;24(16):12978. doi: 10.3390/ijms241612978.

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.尼拉帕利与醋酸阿比特龙治疗转移性去势抵抗性前列腺癌。

J Clin Oncol. 2023 Jun 20;41(18):3339-3351. doi: 10.1200/JCO.22.01649. Epub 2023 Mar 23.

Rucaparib or Physician's Choice in Metastatic Prostate Cancer.芦卡帕利或医生选择治疗转移性前列腺癌。

N Engl J Med. 2023 Feb 23;388(8):719-732. doi: 10.1056/NEJMoa2214676. Epub 2023 Feb 16.

Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease.临床前患者来源的去势抵抗性前列腺癌模型有助于同源重组修复缺陷疾病的个体化评估。

Mol Oncol. 2023 Jun;17(6):1129-1147. doi: 10.1002/1878-0261.13382. Epub 2023 Mar 16.

Olaparib for Metastatic Castration-Resistant Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌。

N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.非 BRCA 种系 DNA 损伤修复基因改变与 PARP 抑制剂芦卡帕利在转移性去势抵抗性前列腺癌中的反应：来自 II 期 TRITON2 研究的分析。

Clin Cancer Res. 2020 Jun 1;26(11):2487-2496. doi: 10.1158/1078-0432.CCR-20-0394. Epub 2020 Feb 21.

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.携带有 BRCA1 或 BRCA2 与 ATM 突变的转移性去势抵抗性前列腺癌男性患者对奥拉帕利治疗的差异化反应。

Eur Urol. 2019 Oct;76(4):452-458. doi: 10.1016/j.eururo.2019.02.002. Epub 2019 Feb 21.

Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer.PTEN 辅助的 G2/M 检查点丧失会阻碍同源重组修复，并增强前列腺癌的放射治疗敏感性和 PARP 抑制剂治疗反应。

Sci Rep. 2018 Mar 2;8(1):3947. doi: 10.1038/s41598-018-22289-7.

Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.聚（ADP-核糖）聚合酶抑制作为开发放射肿瘤学靶标合成致死的模型。

Semin Radiat Oncol. 2010 Oct;20(4):274-81. doi: 10.1016/j.semradonc.2010.06.001.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[Olaparib for high-risk biochemically recurrent prostate cancer following prostatectomy].

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献